NCT00573989 · OUTCOME

Median Progression Free Survival

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer · Source last updated 2019-01-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: years
Interval / dispersion: 95% Confidence Interval
Time frame: 2 years

What was measured

Median Progression Free Survival of participants reported after 2 years.

Analysis population: Data corresponds to Phase II patients.

Groups in this outcome

Erlotinib

Erlotinib erlotinib hydrochloride pemetrexed disodium quality-of-life assessment intensity-modulated radiation therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Erlotinib	12

Reported measurements

Source class 1

Values in years · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Erlotinib	.71	Not reported	.58	.99	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
.58
upper Limit
.99
value
.71

denoms

counts
group Id
OG000
value
12
units
Participants

description

Median Progression Free Survival of participants reported after 2 years.

dispersion Type

95% Confidence Interval

groups

description
Erlotinib erlotinib hydrochloride pemetrexed disodium quality-of-life assessment intensity-modulated radiation therapy
id
OG000
title
Erlotinib

param Type

MEDIAN

population Description

Data corresponds to Phase II patients.

reporting Status

POSTED

time Frame

2 years

title

Median Progression Free Survival

type

SECONDARY

unit Of Measure

years

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice